[The influence of Helicobacter pylori eradication on oesophageal pH-metry and bilimetry results in patients with nonulcer dyspepsia].
Substernal, fasting and night pains with no endoscopic findings in the upper gastrointestinal tract are the leading symptoms of nonulcer dyspepsia (NUD). Our study aimed at determining whether there is duodenogastroesophageal reflux in patients with NUD and to evaluate what role Helicobacter pylori plays in NUD pathophysiology. The study comprised 40 patients, in whom endoscopy, breath test (UBT-13C), 24-hour pH-metry (Digitrapper III) and bilimetry (Bilitec 2000) of the esophagus were performed before and after 7-day antibacterial treatment (pantoprazole 2 x 40 mg, amoxicillin 2 x 1000 mg, clarithromycin 2 x 500 mg). Eradication was achieved in 29 patients, in whom total index of acid reflux (t% pH < 4.0) decreased from 23.1+/-10.4% to 13.1+/-6.2% (p<0.05) and alkaline reflux index (t% abs > 0.14) from 12.9+/-6.3 to 8.1+/-5.7% (p>0.05). Positive correlations between urea breath test results and the indexes of acid (r=0.692) and alkaline refluxes (r=0.246) were observed. In patients with nonulcer dyspepsia infected with Helicobacter pylori complex functional disorders are present. They are expressed as duodenogastroesophageal reflux. The refluxes intensity depends on the extent of Helicobacter pylori infection, which should be remembered when planning antibacterial treatment.
Piotrowski
Wojciech
W
Klinika Gastroenterologii i Chorób Wewnetrznych UM w Lodzi. wojtekp@toya.net.pl
Chojnacki
Jan
J
Gil
Jerzy
J
Walecka-Kapica
Ewa
E
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004383:Duodenogastric Reflux / Q000188:drug therapy* / Q000453:epidemiology*; D004415:Dyspepsia / Q000453:epidemiology*; D005260:Female; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents